Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Background Small increases in bone mass are commonly seen with existing treatments for osteoporosis, which reduce bone remodelling and primarily prevent bone loss.
Since these drugs reduce but do not eliminate risk of fractures, an anabolic agent that would increase bone mass and potentially cure the underlying skeletal problem is needed.
Methods We did a 3-year randomised controlled trial to find out the effects of 1-34 human parathyroid hormone (hPTH [1-34], 400 U/25 mug daily subcutaneously) in postmenopausal women with osteoporosis taking hormone-replacement therapy (n=17).
The controls were women taking hormone-replacement therapy only (n=17).
The primary outcome was bone-mineral density of the lumbar vertebrae, with bone-mineral density at other sites and vertebral fractures as secondary endpoints.
Findings Patients taking hormone-replacement therapy and PTH (1-34) had continuous increase in vertebral bone-mineral density during the 3 years, whereas there was no significant change in the control group.
The total increase in vertebral bone-mineral density was 13.0% (p<0.001) ; 2.7% at the hip (p=0.05) ; and 8.0% in total-body bone mineral (p=0.002).
No loss of bone mass was found at any skeletal site.
Increased bone mass was associated with a reduction in the rate of vertebral fractures, which was significant when fractures were taken as a 15% reduction in vertebral height (p=0.04). (...)
Mots-clés Pascal : Postménopause, Ostéoporose, Incidence, Hormone parathyroïdienne, Colonne vertébrale, Fracture, Randomisation, Femelle, Homme, Evaluation, Appareil génital femelle pathologie, Système ostéoarticulaire pathologie, Activité biologique, Chimiothérapie, Education santé
Mots-clés Pascal anglais : Postmenopause, Osteoporosis, Incidence, Parathyroid hormone, Vertebral column, Fracture, Randomization, Female, Human, Evaluation, Female genital diseases, Diseases of the osteoarticular system, Biological activity, Chemotherapy, Health education
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0438456
Code Inist : 002B02O. Création : 19/12/1997.